Spots Global Cancer Trial Database for advanced solid tumors
Every month we try and update this database with for advanced solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | NCT00732420 | Solid Tumours | topotecan pazopanib | 18 Years - | GlaxoSmithKline | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| TT-702 in Patients With Advanced Solid Tumours. | NCT05272709 | Advanced Solid ... | TT-702 Darolutamide | 16 Years - | Cancer Research UK | |
| M8891 First in Human in Solid Tumors | NCT03138538 | Advanced Solid ... Metastatic Rena... | Part 1: M8891 | 18 Years - | EMD Serono | |
| Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors | NCT02197572 | Advanced Solid ... | Sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma | NCT03439761 | Advanced Solid ... | PT-112 Injectio... | 18 Years - 75 Years | SciClone Pharmaceuticals | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | NCT05867420 | Advanced Solid ... | ASKG915 | 18 Years - | AskGene Pharma, Inc. | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | NCT04972981 | Advanced Solid ... | ADCT-901 | 18 Years - | ADC Therapeutics S.A. | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 | NCT03292783 | Advanced Solid ... | NOV1501 (ABL001... | 19 Years - | ABL Bio, Inc. | |
| Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors | NCT01415297 | Solid Tumors | NKP-1339 | 18 Years - | Intezyne Technologies, Inc. | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | NCT05389462 | Advanced Solid ... | ADCT-601 Gemcitabine | 18 Years - | ADC Therapeutics S.A. | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 | NCT03544905 | Advanced Solid ... | CYH33 for table... | 18 Years - | Haihe Biopharma Co., Ltd. | |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | NCT03409458 | Non-Small Cell ... | PT-112 avelumab | 18 Years - | Promontory Therapeutics Inc. | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | NCT03739138 | Advanced Solid ... | MK-4621 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection | NCT05378737 | Advanced Solid ... | BAT8006 for Inj... | 18 Years - 75 Years | Bio-Thera Solutions | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors | NCT00495144 | Tumors Hypoxia | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | NCT01433991 | Advanced Solid ... | Golvatinib Lenvatinib Lenvatinib | 18 Years - | Eisai Inc. | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors | NCT03713905 | Advanced Solid ... | GLS-010 | 18 Years - 75 Years | Guangzhou Gloria Biosciences Co., Ltd. | |
| ONO-4538 Phase I Study in Patients With Solid Tumor | NCT02261285 | Advanced Solid ... Recurrent Solid... | ONO-4538 | 20 Years - | Ono Pharmaceutical Co. Ltd | |
| Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | NCT01068483 | Breast Cancer Colon Cancer Ovarian Cancer Endometrium Can... | BKM120 | 18 Years - | Novartis | |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors | NCT04623892 | Advanced Solid ... | TQB2618 injecti... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | NCT01235897 | Advanced Solid ... Tumors Cancer | MK-2206 Paclitaxel Trastuzumab | 18 Years - | University of California, San Francisco | |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 | Advanced Solid ... Ovarian Cancer Small Cell Lung... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors | NCT05083481 | Advanced Solid ... | ASP1570 Pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | NCT00618735 | Advanced Solid ... | BIIB021 BIIB021 | 18 Years - | Biogen | |
| A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | NCT05942378 | Advanced Solid ... | HRXG-K-1939 Adebrelimab | 18 Years - 75 Years | Fudan University | |
| Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors | NCT00201812 | Tumors | Etanercept Docetaxel Dexamethasone | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | NCT04169672 | Advanced Solid ... | Surufatinib Toripalimab | 18 Years - 75 Years | Hutchmed | |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470 | Advanced Solid ... | U3-1287 (AMG888... | 18 Years - | U3 Pharma GmbH | |
| Study of AS1411 in Advanced Solid Tumours | NCT00881244 | Advanced Solid ... | AS1411 | 18 Years - | Antisoma Research | |
| Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | NCT02073994 | Cholangiocarcin... Chondrosarcoma Glioma Other Advanced ... | AG-120 | 18 Years - | Servier | |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | NCT03864042 | Advanced Solid ... Metastatic Mela... | losartan dextromethorpha... caffeine omeprazole midazolam rosuvastatin bupropion immed... encorafenib binimetinib modafinil | 18 Years - | Pfizer | |
| First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | NCT01014936 | Patients With S... | MSC2156119J | 18 Years - | EMD Serono | |
| IMX-110 in Patients With Advanced Solid Tumors | NCT03382340 | Solid Tumor, Ad... Advanced Solid ... Pancreatic Canc... Breast Cancer Ovarian Cancer | Imx-110 | 18 Years - | Immix Biopharma, Inc. | |
| Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | NCT04362748 | Advanced Solid ... | AMG 256 | 18 Years - 100 Years | Amgen | |
| Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors | NCT05862831 | Advanced Solid ... | PM1003 Injectio... | 18 Years - 75 Years | Biotheus Inc. | |
| Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | NCT05537987 | Advanced Solid ... | ICP-723 | 18 Years - | InnoCare Pharma Inc. | |
| Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | NCT01139346 | Advanced Solid ... | darinaparsin | 18 Years - | Alaunos Therapeutics | |
| A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | NCT01346358 | Neoplasms | IMC-CS4 | 18 Years - | Eli Lilly and Company | |
| A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors | NCT00557856 | Advanced Solid ... | PF-03446962 | 18 Years - | Pfizer | |
| A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors | NCT00794781 | Advanced Solid ... | E6201 | 18 Years - | Eisai Inc. | |
| Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas | NCT00955292 | Advanced Solid ... Lymphoma | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | NCT01190241 | Advanced Solid ... Inoperable Metastasis | desatinib or su... | 18 Years - | Amsterdam UMC, location VUmc | |
| A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | NCT02318394 | Advanced Solid ... | MEDI0562 | 18 Years - 99 Years | MedImmune LLC | |
| IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors | NCT03665129 | Advanced Solid ... | IPH5401 and Dur... | 18 Years - | Innate Pharma | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. | |
| AMT-562 in Patients With Selected Advanced Solid Tumors | NCT06199908 | Advanced Solid ... | AMT-562 | 18 Years - | Multitude Therapeutics Inc. | |
| Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | NCT04727554 | Advanced Solid ... | AMG 994 AMG 404 | 18 Years - 100 Years | Amgen | |
| Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer | NCT00712504 | Advanced Solid ... Non Small Cell ... | sunitinib docetaxel | 18 Years - | Pfizer | |
| Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors | NCT00605618 | Advanced Solid ... | BMS-777607 | 18 Years - | Bristol-Myers Squibb | |
| A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) | NCT00546247 | Advanced Solid ... | Epofolate | 18 Years - | Bristol-Myers Squibb | |
| The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer | NCT04991129 | Advanced Hemato... Advanced Solid ... | WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 | 18 Years - 75 Years | Suzhou Junjing BioSciences Co., Ltd. | |
| An Investigation of TAS-119 Monotherapy | NCT02448589 | Advanced Solid ... | TAS-119 | 18 Years - | Taiho Oncology, Inc. | |
| Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors | NCT00426582 | Advanced Solid ... | Patupilone | 18 Years - | Novartis | |
| A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | NCT01248949 | Advanced Solid ... Advanced Recurr... | MEDI3617 Bevacizumab Paclitaxel Carboplatin | 18 Years - 99 Years | MedImmune LLC | |
| Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors | NCT06242691 | Advanced Solid ... | MK-1200 Antiemetic | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | NCT01661972 | Metastatic Colo... | Capecitabine an... | 18 Years - | Duke University | |
| Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | NCT00345189 | Tumors Lymphoma | CNF2024 | 18 Years - | Biogen | |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | NCT02546531 | Advanced Solid ... Solid Tumors Pancreatic Canc... | Defactinib Pembrolizumab Gemcitabine | 18 Years - | Washington University School of Medicine | |
| First in Human Trial of TAS266 in Patients With Advanced Solid Tumors | NCT01529307 | Advanced Solid ... | TAS266 | 18 Years - | Novartis | |
| MGD009/MGA012 Combination in Relapsed/Refractory Cancer | NCT03406949 | Advanced Solid ... | obrindatamab retifanlimab | 18 Years - | MacroGenics | |
| Phase I Dose Escalating Study of TKI258 | NCT01471548 | Advanced Solid ... | TKI258 | 20 Years - | Novartis | |
| MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) | NCT00099346 | Colorectal Canc... Advanced Solid ... | MK0457, VX-680 ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases | NCT02187822 | Brain Metastase... Generalized Mal... Brain Lesions | TPI 287 Fractionated St... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies | NCT00831896 | Advanced Solid ... | TAK-701 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients | NCT05823285 | Advanced Solid ... | QLS31903 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | NCT00947739 | Advanced Solid ... Lymphomas | Camptothecin-20... | 18 Years - | New Mexico Cancer Care Alliance |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
